Summary
A total of 25 patients with inoperable cervical cancer were treated by daily radiotherapy (2 Gy); sensitisation was obtained by administration of 5 mg cisplatin 30 min before each irradiation session. The total cumulative dose of cisplatin varied between 50 and 150 mg. A complete kinetic profile (0–24 h) of platinum (Pt) was established after the first dose and at the end of treatment for 22 patients. Pt was quantified by atomic absorption spectrophotometry using Zeeman-effect background correction for trace analysis. The total Pt AUC0–24 h increased from 1.53±0.77 to 7±3.55 μg·h·ml−1 between the start and the end of treatment (P<0.001). Ultrafilterable Pt (Pt UF) rose from 0.079±0.038 to 0.138±0.095 μg·h·ml−1 (P<0.01). Elimination half-lives were unchanged for total Pt but rose for Pt UF; these kinetic modifications in Pt UF did not correlate with any significant change in individual serum creatinine levels. No clear correlation was found between the cumulative cisplatin dose and tumor levels measured in 13 patients, and the tumor cisplatin dose did not correlate with response to treatment. Patients with hematological toxicity were characterised by an increase in their residual Pt UF level during treatment. Overall, our findings strengthen the notion of Pt UF kinetic variability during repeated treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Balis FM, Holcenberg JS, Bleyer WA (1983) Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 8: 202–232
Bellamy AS, Hill BT (1984) Interactions between clinically effective antitumor drugs and radiation in experimental systems. Biochem Biophys Acta 738: 125–166
Boven E, Van der Vijgh WJF, Nauta NM, Schluper HMM, Pinedo HM (1985) Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res 45: 86–90
Campbell BA, Kalman SM, Jacobs C (1983) Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 67: 169–172
Daugaard G, Abildgaard U, Holstaine-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP (1988) Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44: 164–172
Dewitt L (1987) Combined treatment of radiation andcis-diamminedichloroplatinum(II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13: 403–426
Dominici C, Petrucci F, Caroli S, Alimonti A, Clerico A, Castello MA (1989) A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors. J Clin Oncol 7: 100–107
Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction ofcis-diammine (1,1-cyclobutanedicarboxytals) platinum in patients with impaired renal function. Cancer Res 44: 5432–5436
Fjeldborg P, Sorensen J, Helkjaer PE (1986) The long-term effect of cisplatin on renal function. Cancer 58: 2214–2217
Forastière AA, Belliveau JF, Goren MP, Vogel WC, Posner MR, O'Leary GP (1988) Pharmacokinetic and toxicity evaluation of fiveday continous infusion versus intermittent boluscis-diamminedichloroplatinum(II) in head and neck cancer patients. Cancer Res 48: 3869–3874
Hecquet B, Vennin P, Fournier C, Poissonnier B (1987) Evaluation of the pharmacological benefit and determination of the influencing factors of intra-arterialcis-diamminedichloroplatinum administration in patients with uterine cervical cancer. Cancer Res 47: 6134–6137
Jaffe N, Keifer R, Robertson R, Cangir A, Wang A (1987) Renal toxicity with cumulative doses ofcis-diamminedichloroplatinum(II) in pediatric patients with osteosarcoma. Effect on creatinine clearance and methotrexate excretion. Cancer 59: 1577–1581
Litterst CL, Leroy AF, Guarino AM (1979) Disposition and distribution of platinum following parenteral administration ofcis-dichlorodiammineplatinum(II) to animals. Cancer Treat Rep 63: 1485–1492
Newell DR, Siddik ZH, Gumbrell LA, Boxall FE, Gore ME, Smith IE, Calvert AH (1987) Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol 23: 1399–1405
Reece PA, Stafford I, Russel J, Gill PG (1986) Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin. J Clin Oncol 4: 1392–1398
Reece PA, Stafford I, Russel J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin; relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5: 304–309
Van Harskamp G, Boven E, Vermorken JB, Van Deutekom H, Stam J, Njo KH, Karim ABMF, Tierie AH, Golding RP, Pinedo HM (1987) Phase II trial of combined radiotherapy and daily low-dose cisplatin for inoperable, locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 13: 1735–1738
Wile AG, Kar R, Cohen RA, Jakowatz JG, Opfell RW (1986) The pharmacokinetics of cisplatin in experimental regional chemotherapy. Cancer 59: 695–700
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Milano, G., Troger, V., Courdi, A. et al. Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser. Cancer Chemother. Pharmacol. 27, 55–59 (1990). https://doi.org/10.1007/BF00689277
Issue Date:
DOI: https://doi.org/10.1007/BF00689277